This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Parts of this article read like an advert and its cardiac risk is understated when looking at geriatric mortality, the only research I could find
Mirtazapine is known to cause hyponatremia in some patients and is therefore is a potential slow sodium channel blocker with cardiac symptoms typically appearing around a month after treatment, it just isn't a "fast" sodium channel blocker. This is from one of many peer reviewed journals that actually bother to include Mirtazapine in safety studies. The results on safety are questionable beyond specific cases such as general risks of overdose in people with no co-morbidities or tcas and it's cardiac safety in general is questionable compared to ssris Maiakaat (talk) 12:12, 21 November 2023 (UTC)[reply]
